Table 3. Odds of adverse outcome in snakebite patients treated with different antivenoms at Abdurafi field hospital between 2015 and 2019.

Antivenom	n	Adverse outcome (%)	Odds ratio (95% CI)	p-value	Adjusted odds ratio*** (95% CI)	p-value
Fav-Afrique	148*	10 (6.8%)	1.00 (reference)
VacSera	164	42 (25.6%)	4.72 (2.27–9.80)	<0.001	6.16 (2.64–14.4)	<0.001
EchiTAb-PLUS-ICP	155**	15 (9.6%)	1.47 (0.64–3.38)	0.367	3.16 (1.12–8.00)	0.029

* excluding one patient who defaulted treatment (discharged against medical advice)

** excluding one patient who had missing data for heart rate

*** adjusted for age, sex, and time from bite until admission (a priori) and signs of severe envenomation, body part bitten, heart rate and temperature on admission (associated with outcome and antivenom)